Alexander Boman Ho Henderson, Program Director

Alex completed his studies in London, England (UK), obtaining a MSc in Cell and Gene Therapy and a PhD in Cell Biology at University College London, in collaboration with GlaxoSmithKline. To get a better understanding of private funding mechanisms for novel therapeutic translation he gained experience in biotechnology-focused venture capital (MBX Capital) and investment banking (Chardan Capital Markets) in New York City before returning to academic research as a Program Manager. Alex joins us from Lorenz Studer’s laboratory at Memorial Sloan Kettering Institute, where he managed a well-funded collaborative research program of 5 PIs and ~50 lab members across New York, Boston, Chicago and Australia. In this role, he has built critical experience in facilitating cutting edge research for target discovery and led key genome-wide CRISPR-KO screening experiments in clinically relevant hPSC-derived dopamine neuron models of Parkinson’s disease. Alex brings to MGH a wealth of knowledge in generating and validating hPSC-derived neurodegenerative models, coordinating and implementing program research strategy, in addition to having a successful track record in obtaining research funds for new projects. On a personal level, he shares a drive and passion for novel therapeutic translation for devastating neurodegenerative diseases such as ALS and is excited to work with everyone to try and make this a reality. In his non-working life, he enjoys spending quality time with his family and friends and has a strong passion for Soccer (football) and cooking/eating.